Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care

Journal of Nuclear Medicine

Volumn 48, Issue 1 SUPPL., 2007, Pages

  Israel, Ora ^a,b   Kuten, Abraham ^a,b  

^a Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

18F FDG; Cancer; PET CT; Recurrence

Indexed keywords

AROMATASE INHIBITOR; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; LETROZOLE; RADIOACTIVE IODINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BREAST CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LARYNGEAL BIOPSY; LARYNX EDEMA; LIVER METASTASIS; LUNG CANCER; MASTECTOMY; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SYSTEMATIC REVIEW; THYROID CANCER; WHOLE BODY IMAGING; WHOLE BODY SCINTISCANNING; BIOMEDICAL TECHNOLOGY ASSESSMENT; IMAGE SUBTRACTION; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEM ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; SYSTEMS INTEGRATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 33947592059     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol. 2004;15(suppl 4):iv103-iv106.
2. Bakalakos EA, Burak WE, Young DC, et al. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases? Am J Surg. 1999;177:2-6.
3. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg. 1996;83:293-304.
4. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci. 2001;38:225-262.
5. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res. 2001;21:1375-1378.
6. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862-869.
7. Bohm B, Schwenk W, Huche H, et al. Does methodic long-term follow up affect survival after curative resection of colorectal carcinoma? Dis Colon Rectum. 1993;36:280-286.
8. Patt YZ, Lamki LM, Shanken J, et al. Imaging with indium-111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990;8:1246-1254.
9. Fleming LW. Playing the waiting game: the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca-125 levels. Scott Med J. 2001;46:81-83.
10. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role for whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2- deoxy-D-glucose. Eur J Nucl Med. 2002;29:797-803.
11. Arulampalam TH, Costa DC, Loizidou M, Visvikis D, Ell PJ, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg. 2001;88:176-189.
12. Zervos EE, Badgwell BD, Burak WE, et al. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636-644.
13. Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of earlystage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2001;122:891-899.
14. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
15. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging. 2001;26:254-259.
16. Krestin GP, Steinbrich W, Friedmann G. Recurrent rectal cancer: diagnosis with MR imaging versus CT. Radiology. 1988;168:307-311.
17. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
18. Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2- deoxyglucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310-315.
19. 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? J Nucl Med. 2004;45:2045-2051.
20. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177-1189.
21. Cook GJ, Maisey MN, Fogelman I. Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
22. Kostakoglu L, Agress H, Goldsmith J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315-340.
23. 18F-fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
24. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379.
25. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
26. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
27. Cooper DL, Neumann RD, Caride VJ. A critical assessment of the prognostic value of gallium-67 scintigraphy in lymphoma. In: Freeman L, ed. Nuclear Medicine Annual 2000. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:211-232.
28. Yoon LS, Haims AH, Brink JA, et al. Evaluation of an emergency radiology quality assurance program at a level I trauma center: abdominal and pelvic CT studies. Radiology. 2002;224:42-46.
29. Bipat S, van Leeuwen MS, Comans EFI, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology. 2005;237:123-131.
30. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027-1034.
31. Veit P, Antoch G, Stergar H, et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80-87.
32. Even-Sapir E, Parag Y, Lerman H, et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdomino-perineal or anterior resection. Radiology. 2004;232:815-822.
33. 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005;46:587-595.
34. Votrubova J, Belohlavek O, Jaruskova M, et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2006;33:779-784.
35. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797-1803.
36. 18F-FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2000;47:24-34.
37. 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol. 2004;94:680-684.
38. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792-797.
39. Bristow RE, Giuntoli RL, Pannu HK, et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol. 2005;99:294-300.
40. Hauth EA, Antoch G, Stattaus J, et al. Evaluation of integrated whole-body PET/ CT in the detection of recurrent ovarian cancer. Eur J Radiol. 2005;56:263-268.
41. Isasi CR, Moadel R, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105-112.
42. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005;7:369-376.
43. Tastumi M, Cohade C, Mourtzikos M, et al. Initial experience with FDG-PET/ CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging. 2006;33:254-262.
44. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med. 2005;46:1356-1367.
45. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237:627-634.
46. Fogelman I. Osteoblastic bone metastases in breast cancer: is not seeing believing? Eur J Nucl Med Mol Imaging. 2005;32:1250-1252.
47. Vlastos G, Smith DL, Singletary E, et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol. 2004;11:869-874.
48. Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patients following curative-intent therapy. Chest. 2003;123:272S-283S.
49. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology. 1994;191:379-382.
50. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med. 2002;32:240-271.
51. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640-1646.
52. Schoder H, Yeung HWD, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65-72.
53. Gordin A, Daitzchman M, Doweck I, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope. 2006;116:273-278.
54. 18F fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107-1113.
55. Zimmer LA, McCook B, Meltzer C, et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg. 2003;128:178-184.
56. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005;115:237-243.
57. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616-624.
58. Saab G, Driedger AA, Pavlovsky W, et al. Thyroid-stimulating hormonestimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in (131)I-negative papillary thyroid carcinoma. Thyroid. 2006;16:267-272.
59. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002;53:89-112.